Published in Mol Cancer Ther on October 01, 2008
Children's Oncology Group's 2013 blueprint for research: bone tumors. Pediatr Blood Cancer (2012) 1.20
Safety concern between autologous fat graft, mesenchymal stem cell and osteosarcoma recurrence. PLoS One (2010) 1.01
Novel strategies for the treatment of chondrosarcomas: targeting integrins. Biomed Res Int (2013) 0.98
Effect of zoledronic acid and amputation on bone invasion and lung metastasis of canine osteosarcoma in nude mice. Clin Exp Metastasis (2011) 0.88
State-of-the-art approach for bone sarcomas. Eur J Orthop Surg Traumatol (2014) 0.82
Bone sarcomas: from biology to targeted therapies. Sarcoma (2012) 0.82
RANK and RANK ligand expression in primary human osteosarcoma. J Bone Oncol (2015) 0.82
Osteosarcoma: Cells-of-Origin, Cancer Stem Cells, and Targeted Therapies. Stem Cells Int (2016) 0.81
Therapeutic effect of nanogel-based delivery of soluble FGFR2 with S252W mutation on craniosynostosis. PLoS One (2014) 0.78
Bone Tumor Environment as a Potential Therapeutic Target in Ewing Sarcoma. Front Oncol (2015) 0.78
Extracellular Membrane Vesicles Derived from 143B Osteosarcoma Cells Contain Pro-Osteoclastogenic Cargo: A Novel Communication Mechanism in Osteosarcoma Bone Microenvironment. Transl Oncol (2014) 0.77
Human mesenchymal stem cells as delivery of osteoprotegerin gene: homing and therapeutic effect for osteosarcoma. Drug Des Devel Ther (2015) 0.77
Anti-RANKL therapy for bone tumours: Basic, pre-clinical and clinical evidences. J Bone Oncol (2012) 0.76
RANK-RANKL signalling in cancer. Biosci Rep (2016) 0.75
Regulation of cancer cell migration and bone metastasis by RANKL. Nature (2006) 5.27
Osteosarcoma: anatomic and histologic variants. Am J Clin Pathol (2006) 2.71
Osteoprotegerin inhibits prostate cancer-induced osteoclastogenesis and prevents prostate tumor growth in the bone. J Clin Invest (2001) 2.49
Chimeric anti-TNF-alpha monoclonal antibody cA2 binds recombinant transmembrane TNF-alpha and activates immune effector functions. Cytokine (1995) 2.34
CD4(+) regulatory T cells in autoimmunity and allergy. Curr Opin Immunol (2002) 2.25
Human antibodies from transgenic animals. Nat Biotechnol (2005) 2.04
Osteoprotegerin and RANKL regulate bone resorption, density, geometry and strength. Curr Opin Pharmacol (2005) 2.03
Osteoprotegerin inhibits the development of osteolytic bone disease in multiple myeloma. Blood (2001) 1.83
Osteoprotegerin is a soluble decoy receptor for tumor necrosis factor-related apoptosis-inducing ligand/Apo2 ligand and can function as a paracrine survival factor for human myeloma cells. Cancer Res (2003) 1.58
RANKL/RANK/OPG: new therapeutic targets in bone tumours and associated osteolysis. Biochim Biophys Acta (2004) 1.57
Soluble receptor activator of nuclear factor kappaB Fc diminishes prostate cancer progression in bone. Cancer Res (2003) 1.55
Role of osteoprotegerin (OPG) in cancer. Clin Sci (Lond) (2006) 1.51
Osteoprotegerin (OPG) is a survival factor for human prostate cancer cells. Cancer Res (2002) 1.50
Mechanisms of cancer metastasis to the bone. Cell Res (2005) 1.49
Molecular mechanisms of breast cancer metastases to bone. Clin Breast Cancer (2005) 1.46
Osteoprotegerin inhibits osteolysis and decreases skeletal tumor burden in syngeneic and nude mouse models of experimental bone metastasis. Cancer Res (2001) 1.44
A nonionic amphiphile agent promotes gene delivery in vivo to skeletal and cardiac muscles. Hum Gene Ther (2002) 1.37
Characterization of structural domains of human osteoclastogenesis inhibitory factor. J Biol Chem (1998) 1.33
Therapeutic relevance of osteoprotegerin gene therapy in osteosarcoma: blockade of the vicious cycle between tumor cell proliferation and bone resorption. Cancer Res (2007) 1.26
Osteoprotegerin (OPG) produced by bone marrow stromal cells protects breast cancer cells from TRAIL-induced apoptosis. Breast Cancer Res Treat (2004) 1.25
Do CD4+ CD25+ immunoregulatory T cells hinder tumor immunotherapy? J Immunother (2002) 1.25
Antibody engineering via genetic engineering of the mouse: XenoMouse strains are a vehicle for the facile generation of therapeutic human monoclonal antibodies. J Immunol Methods (1999) 1.23
Fully human therapeutic monoclonal antibodies. J Immunother (2005) 1.20
Mixed metastatic lung cancer lesions in bone are inhibited by noggin overexpression and Rank:Fc administration. J Bone Miner Res (2006) 1.18
RANKL, RANK, osteoprotegerin: key partners of osteoimmunology and vascular diseases. Cell Mol Life Sci (2007) 1.14
Therapeutic efficacy of a soluble receptor activator of nuclear factor kappaB-IgG Fc fusion protein in suppressing bone resorption and hypercalcemia in a model of humoral hypercalcemia of malignancy. Cancer Res (2001) 1.13
TNF-related activation-induced cytokine (TRANCE) induces angiogenesis through the activation of Src and phospholipase C (PLC) in human endothelial cells. J Biol Chem (2001) 1.08
The effects of RANK blockade and osteoclast depletion in a model of pure osteoblastic prostate cancer metastasis in bone. J Orthop Res (2005) 1.04
Osteoprotegerin/osteoclastogenesis inhibitory factor decreases human prostate cancer burden in human adult bone implanted into nonobese diabetic/severe combined immunodeficient mice. Cancer Res (2003) 1.04
Breast cancer: bisphosphonate therapy for metastatic bone disease. Clin Cancer Res (2006) 1.03
Osteoprotegerin prevents and reverses hypercalcemia in a murine model of humoral hypercalcemia of malignancy. Cancer Res (2000) 1.03
Negatively charged self-assembling DNA/poloxamine nanospheres for in vivo gene transfer. Nucleic Acids Res (2004) 1.02
Vascular endothelial growth factor up-regulates expression of receptor activator of NF-kappa B (RANK) in endothelial cells. Concomitant increase of angiogenic responses to RANK ligand. J Biol Chem (2003) 0.98
Amphiphilic block copolymers promote gene delivery in vivo to pathological skeletal muscles. Hum Gene Ther (2005) 0.98
Human osteosarcoma cells express functional receptor activator of nuclear factor-kappa B. J Pathol (2007) 0.98
Receptor activator of nuclear factor-kappaB ligand (RANKL) directly modulates the gene expression profile of RANK-positive Saos-2 human osteosarcoma cells. Oncol Rep (2007) 0.96
RANKL directly induces bone morphogenetic protein-2 expression in RANK-expressing POS-1 osteosarcoma cells. Int J Oncol (2006) 0.95
The treatment of osteosarcoma of the extremities: twenty year's experience at the Istituto Ortopedico Rizzoli. Cancer (1981) 0.94
Nonionic amphiphilic block copolymers promote gene transfer to the lung. Hum Gene Ther (2005) 0.92
RANK-Fc: a therapeutic antagonist for RANK-L in myeloma. Cancer (2003) 0.88
Receptor activator of NF-kappa B ligand inhibition suppresses bone resorption and hypercalcemia but does not affect host immune responses to influenza infection. J Immunol (2007) 0.87
Inhibition of lung metastasis of osteosarcoma cell line POS-1 transplanted into mice by thigh ligation. Cancer Lett (2002) 0.86
Osteoprotegrin and the bone homing and colonization potential of breast cancer cells. J Cell Biochem (2008) 0.86
The role of TNF-related activation-induced cytokine-receptor activating NF-kappa B interaction in acute allograft rejection and CD40L-independent chronic allograft rejection. J Immunol (2004) 0.84
Retrovirus-mediated gene transfer of receptor activator of nuclear factor-kappaB-Fc prevents bone loss in ovariectomized mice. Stem Cells (2006) 0.83
IL-6, RANKL, TNF-alpha/IL-1: interrelations in bone resorption pathophysiology. Cytokine Growth Factor Rev (2004) 2.72
The molecular triad OPG/RANK/RANKL: involvement in the orchestration of pathophysiological bone remodeling. Cytokine Growth Factor Rev (2004) 2.35
The KCNQ1 potassium channel is down-regulated by ubiquitylating enzymes of the Nedd4/Nedd4-like family. Cardiovasc Res (2007) 2.03
Mechanisms of bone repair and regeneration. Trends Mol Med (2009) 1.61
Current therapeutic strategies and novel approaches in osteosarcoma. Cancers (Basel) (2013) 1.42
Opposite Effects of Soluble Factors Secreted by Adipose Tissue on Proliferating and Quiescent Osteosarcoma Cells. Plast Reconstr Surg (2016) 1.40
Receptor activator of nuclear factor kappaB ligand (RANKL)/osteoprotegerin (OPG) ratio is increased in severe osteolysis. Am J Pathol (2003) 1.38
Useful side handle for holding needle during ultrasound-guided regional anesthesia. Reg Anesth Pain Med (2009) 1.38
Zoledronic acid suppresses lung metastases and prolongs overall survival of osteosarcoma-bearing mice. Cancer (2005) 1.30
Induction of osteogenesis in mesenchymal stem cells by activated monocytes/macrophages depends on oncostatin M signaling. Stem Cells (2012) 1.29
Therapeutic relevance of osteoprotegerin gene therapy in osteosarcoma: blockade of the vicious cycle between tumor cell proliferation and bone resorption. Cancer Res (2007) 1.26
Recent advances in TGF-beta effects on chondrocyte metabolism. Potential therapeutic roles of TGF-beta in cartilage disorders. Cytokine Growth Factor Rev (2002) 1.24
Bisphosphonates: new therapeutic agents for the treatment of bone tumors. Trends Mol Med (2004) 1.19
Zoledronic acid as a new adjuvant therapeutic strategy for Ewing's sarcoma patients. Cancer Res (2010) 1.12
Interleukin-34 is expressed by giant cell tumours of bone and plays a key role in RANKL-induced osteoclastogenesis. J Pathol (2010) 1.11
Zoledronic acid potentiates mTOR inhibition and abolishes the resistance of osteosarcoma cells to RAD001 (Everolimus): pivotal role of the prenylation process. Cancer Res (2010) 1.10
Self-assembled lamellar complexes of siRNA with lipidic aminoglycoside derivatives promote efficient siRNA delivery and interference. Proc Natl Acad Sci U S A (2007) 1.08
Proteoglycans: key partners in bone cell biology. Bioessays (2007) 1.07
Concise review: embryonic stem cells: a new tool to study osteoblast and osteoclast differentiation. Stem Cells (2006) 1.07
Self-assembly and characterization of layered double hydroxide/DNA hybrids. Nano Lett (2006) 1.05
Zoledronic acid slows down rat primary chondrosarcoma development, recurrent tumor progression after intralesional curretage and increases overall survival. Int J Cancer (2006) 1.04
Long-circulating DNA lipid nanocapsules as new vector for passive tumor targeting. Biomaterials (2009) 1.02
Osteoprotegerin: multiple partners for multiple functions. Cytokine Growth Factor Rev (2013) 1.02
OPG/membranous--RANKL complex is internalized via the clathrin pathway before a lysosomal and a proteasomal degradation. Bone (2006) 1.02
Glycosaminoglycans as potential regulators of osteoprotegerin therapeutic activity in osteosarcoma. Cancer Res (2009) 1.01
Developing cell therapy techniques for respiratory disease: intratracheal delivery of genetically engineered stem cells in a murine model of airway injury. Hum Gene Ther (2009) 1.01
Safety concern between autologous fat graft, mesenchymal stem cell and osteosarcoma recurrence. PLoS One (2010) 1.01
CCL5 neutralization restricts cancer growth and potentiates the targeting of PDGFRβ in colorectal carcinoma. PLoS One (2011) 1.00
Mesenchymal stem cells induce a weak immune response in the rat striatum after allo or xenotransplantation. J Cell Mol Med (2009) 1.00
Trafficking-deficient long QT syndrome mutation KCNQ1-T587M confers severe clinical phenotype by impairment of KCNH2 membrane localization: evidence for clinically significant IKr-IKs alpha-subunit interaction. Heart Rhythm (2009) 0.98
Amphiphilic block copolymers promote gene delivery in vivo to pathological skeletal muscles. Hum Gene Ther (2005) 0.98
Pericyte-like progenitors show high immaturity and engraftment potential as compared with mesenchymal stem cells. PLoS One (2012) 0.98
Downregulation of osteoblast markers and induction of the glial fibrillary acidic protein by oncostatin M in osteosarcoma cells require PKCdelta and STAT3. J Bone Miner Res (2004) 0.98
Oxytocin reverses ovariectomy-induced osteopenia and body fat gain. Endocrinology (2014) 0.96
Receptor activator of nuclear factor-kappaB ligand (RANKL) directly modulates the gene expression profile of RANK-positive Saos-2 human osteosarcoma cells. Oncol Rep (2007) 0.96
Autophagy in osteoblasts is involved in mineralization and bone homeostasis. Autophagy (2014) 0.96
Carotid and femoral atherosclerotic plaques show different morphology. Atherosclerosis (2011) 0.96
Preclinical evidence that use of TRAIL in Ewing's sarcoma and osteosarcoma therapy inhibits tumor growth, prevents osteolysis, and increases animal survival. Clin Cancer Res (2010) 0.96
RANKL directly induces bone morphogenetic protein-2 expression in RANK-expressing POS-1 osteosarcoma cells. Int J Oncol (2006) 0.95
Inducible production of erythropoietin using intramuscular injection of block copolymer/DNA formulation. J Gene Med (2005) 0.94
A combination of methotrexate and zoledronic acid prevents bone erosions and systemic bone mass loss in collagen induced arthritis. Arthritis Res Ther (2009) 0.94
BYL719, a new α-specific PI3K inhibitor: single administration and in combination with conventional chemotherapy for the treatment of osteosarcoma. Int J Cancer (2014) 0.94
Interleukin-34 promotes tumor progression and metastatic process in osteosarcoma through induction of angiogenesis and macrophage recruitment. Int J Cancer (2014) 0.94
Role for interleukin-6 in structural joint damage and systemic bone loss in rheumatoid arthritis. Joint Bone Spine (2010) 0.93
Cancer-specific transgene expression mediated by systemic injection of nanoparticles. Cancer Res (2009) 0.92
Nonionic amphiphilic block copolymers promote gene transfer to the lung. Hum Gene Ther (2005) 0.92
Targeting the EWSR1-FLI1 oncogene-induced protein kinase PKC-β abolishes ewing sarcoma growth. Cancer Res (2012) 0.92
Non-viral nanosystems for systemic siRNA delivery. Pharmacol Res (2009) 0.91
Killer dendritic cells link innate and adaptive immunity against established osteosarcoma in rats. Cancer Res (2008) 0.91
First preclinical imaging of primary cartilage neoplasm and its local recurrence using 99mTc-NTP 15-5 radiotracer. J Nucl Med (2009) 0.90
Tumor transfection after systemic injection of DNA lipid nanocapsules. Biomaterials (2010) 0.90
Differentiation of osteoblasts from mouse embryonic stem cells without generation of embryoid body. In Vitro Cell Dev Biol Anim (2007) 0.90
Mifamurtide for the treatment of nonmetastatic osteosarcoma. Expert Opin Pharmacother (2011) 0.89
The encapsulation of DNA molecules within biomimetic lipid nanocapsules. Biomaterials (2009) 0.89
Proteoglycans on bone tumor development. Drug Discov Today (2010) 0.89
mTOR inhibitors (rapamycin and its derivatives) and nitrogen containing bisphosphonates: bi-functional compounds for the treatment of bone tumours. Curr Med Chem (2007) 0.89
TRAIL receptor signaling and therapeutic option in bone tumors: the trap of the bone microenvironment. Am J Cancer Res (2011) 0.88
Distinct roles of Bcl-2 and Bcl-Xl in the apoptosis of human bone marrow mesenchymal stem cells during differentiation. PLoS One (2011) 0.88
AFP-specific immunotherapy impairs growth of autochthonous hepatocellular carcinoma in mice. J Hepatol (2010) 0.88
RANKL/RANK/OPG: key therapeutic target in bone oncology. Curr Drug Discov Technol (2008) 0.87
Osteosarcoma: current status of immunotherapy and future trends (Review). Oncol Rep (2006) 0.87
Therapy of anemia in kidney failure, using plasmid encoding erythropoietin. Hum Gene Ther (2008) 0.87